Figure 4.

TFRD protects against AFB1–induced alterations in plasma metabolite. (A) OPLS–DA of the CON and AFB1 groups. (B) OPLS–DA of the AFB1 and A + T groups. (C) Heatmap of metabolite content clustering. (D) Metabolite abundance analysis by LC–MS/MS. (E) Ternary analysis shows the relative abundance of metabolites in different groups. AM, Amino acid and its metabolomics; GP, Glycerol phospholipids; OD, Organic acid and their derivatives; FA, Fatty acyl; NM, Nucleotide and its metabolomics; BSD, Benzene and substituted derivatives; HC, Heterocyclic compounds; CM, Carbohydrates and its metabolites; AA, Alcohol and amines; SL, Sphingolipids; BA, Bile acids; CoEV, CoEnzyme and vitamins; HHRC, Hormones and hormone-related compounds; TCP, Tryptamines, Cholines, Pigments; AKE, Aldehyde, Ketones, Esters; and PD, Pteridines and derivatives. (F,G) Metabolic pathway analysis based on significantly differential metabolites from the CON, AFB1, and A + T groups. The color of the dots is p value, and the redder the color, the more significant the enrichment. Differences between groups were analyzed by Student’s t-test. PS, Parathyroid hormone synthesis, secretion and action; ER, Endocrine and other factor-regulated calcium reabsorption.